What Has Been The Evolution of the Cancer AnorexiaCachexia Syndrome CACS Market in Recent Years?
The cancer anorexiacachexia syndrome cacs market has seen considerable growth due to a variety of factors.
• The market for the cancer anorexia-cachexia syndrome (CACS) has expanded swiftly in the past few years. Predictions point towards an increase from $3.51 billion in 2024 to $3.89 billion in 2025 with a compound annual growth rate (CAGR) of 11.0%.
This substantial growth during the historical period can be associated with factors such as a rise in cancer cases, more awareness among healthcare providers, an improved emphasis on cancer patients' quality of life, the growth of clinical trials, and alliances and partnerships within the pharmaceutical industry.
What Is the Forecasted Market Size and Growth Rate for The Cancer AnorexiaCachexia Syndrome CACS Market By 2029?
The cancer anorexiacachexia syndrome cacs market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for the cancer anorexia-cachexia (CACS) market to experience accelerated growth in the coming years. A projection of $5.84 billion by 2029 is set, with a compound annual growth rate (CAGR) of 10.7%.
A combination of factors such as higher survival rates in cancer patients, a surge in investments towards oncology supportive care, the expansion of personalized medicine, a heightened emphasis on multimodal therapies, and robust healthcare infrastructure can be attributed to this growth trajectory. Key trends influencing this period of growth incorporate advancements in palliative care, the evolution of targeted therapies, technological progress in drug delivery systems, the application of AI in drug development, and an escalated focus on personalized medicine.
What Are The Leading Drivers Of Growth In The Cancer AnorexiaCachexia Syndrome CACS Market?
The surge in cancer cases is anticipated to stimulate the expansion of the cancer anorexia-cachexia syndrome market in the future. Cancer, a term encapsulating various diseases distinguished by unrestrained proliferation and dissemination of anomalous cells in the body, is experiencing a global upspring. This escalation is attributable to factors like an aging population, lifestyle alterations, environmental factors, advancements in detection techniques, heightened awareness, as well as certain cancer-linked infections and genetic susceptibilities. Cancer anorexia-cachexia syndrome (CACS) contributes to managing the widespread occurrence of cancer by focusing on severe weight loss and malnutrition typically observed in cancer patients, which in turn enhances their overall well-being and treatment results. For instance, a report from the UK-based charity, Macmillan Cancer Support, released in August 2024, stated that over 3 million residents in the UK are presently coping with cancer. This figure is projected to climb to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. As such, the mounting prevalence of cancer is fuelling the cancer anorexia-cachexia syndrome market's growth.
What Are The Main Segments Of The Global Cancer AnorexiaCachexia Syndrome CACS Market?
The cancer anorexia-cachexia syndrome (CACS) market covered in this report is segmented –
1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications
2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics
3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions
4) By Route of Administration: Oral, Intravenous, Subcutaneous, Transdermal, Other Route of Administration
5) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators
2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists
3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)
4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors
5) By Other Indications: Combination Therapies, Supportive Care Interventions
Pre-Book The Cancer AnorexiaCachexia Syndrome CACS Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Cancer AnorexiaCachexia Syndrome CACS Market?
Key players in the cancer anorexia-cachexia syndrome market are striving to create groundbreaking solutions like monoclonal antibody therapies. These efforts aim to boost treatment efficiency, enhance patient prognosis, and cater to underserved clinical necessities. Monoclonal antibody therapies are innovative treatments that utilize laboratory-engineered antibodies to single out specific antigens on cancer cells, thereby amplifying the immune system's ability to identify and counter them. In September 2024, for example, Pfizer Inc., a renowned pharmaceutical and biotechnology firm in the US, published encouraging results from the Phase II clinical study of their monoclonal antibody, ponsegromab, which targets Growth/Differentiation Factor 15 (GDF-15). The promising findings from this research present a new potential avenue of treatment for individuals battling this challenging ailment, which currently has only a handful of effective treatments available. The results from the Phase 2 trial suggest noticeable strides in addressing the inflammatory processes at the root of muscle wasting and weight loss in cancer sufferers. This treatment approach seeks to not only enhance physical function but also improve the overall life quality of cancer patients, representing a crucial advancement in cancer care.
Who Are the Key Players In The Cancer AnorexiaCachexia Syndrome CACS Market?
Major companies operating in the cancer anorexia-cachexia syndrome (CACS) market are:
• Pfizer Inc.
• Merck & Co. Inc.
• Ono Pharmaceutical Co. Ltd.
• Mundipharma International Limited
• Yuhan Corporation
• Helsinn Healthcare SA
• AVEO Pharmaceuticals Inc.
• NGM Biopharmaceuticals Inc.
• Larix Bioscience LLC
• Aeterna Zentaris Inc.
• Artelo Biosciences Inc.
• Sapphire Therapeutics Inc.
• Endevica Bio
• AAVogen Inc.
• Actimed Therapeutics Ltd.
• Aphios Corporation
• Betula Pharmaceuticals AB
• Cannabics Pharmaceuticals Inc.
• Creative Medical Technology Holdings Inc.
• Abreos Biosciences Inc.
What Is The Most Dominant Region In The Cancer AnorexiaCachexia Syndrome CACS Market?
North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
